Article citationsMore>>

Motzer, R.J., Alekseev, B., Rha, S.Y., Porta, C., Eto, M., Poweles, T., et al. (2021) Levantinib Plus Pembrolizumab or Levantinib Plus Everolimus for Advanced Renal Cell carcinoma: A Randomised, Open-Label, Phase 3 Trial. Lancet Oncology, 22, 957-970.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top